About
Overview
Company Leadership
Science
Technology Platform
Scientific Publications
Pipeline
Overview
CF101
CF102
CF602
Investor Information
Overview
News / Events
Company Information
Financial Information
Stock Information
SEC Filings
Corporate Governance
Shareholders Meetings
Contact Us
Directions
Investor Information
Overview
News / Events
Press Releases
In The News
Research
Events Calendar
Presentations
Email Alerts
Company Information
Profile
Management
IR Contacts
FAQ
Financial Information
Quarterly & Annual Reports
Stock Information
Quote
Charts
Historical Data
SEC Filings
All SEC Filings
Section 16 Filings
Corporate Governance
Board of Directors
Governance Docs
Shareholders Meetings
Email Alerts
IR Contacts
RSS News Feed
Press Releases
All News
By Year:
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
Mar 28, 2018 7:00 AM EDT
Can-Fite to Present at the MicroCap Conference
Mar 23, 2018 7:00 AM EDT
Can-Fite Reports 2017 Financial Results & Provides Clinical Update
Mar 14, 2018 7:00 AM EDT
Can-Fite to Present at the NASH 2nd Annual H.C. Wainwright Investor Conference
Mar 9, 2018 9:00 AM EST
Can-Fite BioPharma Announces $5 Million Registered Direct Offering
Mar 6, 2018 7:00 AM EST
Can-Fite to Participate in Panel Discussions on Latest Drug Developments in NASH at the 30th Annual ROTH Conference
Mar 5, 2018 7:00 AM EST
Can-Fite to Present at the Inaugural LD Micro Virtual Conference
Feb 28, 2018 9:25 AM EST
Can Fite Reports on the Progress of its Phase II NASH Study with Drug Candidate Namodenoson
Feb 22, 2018 8:00 AM EST
Can Fite Announces the Submission of Safety Reports for Piclidenoson and Namodenoson to FDA and other Regulatory Authorities Showing Favorable Safety Profile
Feb 12, 2018 7:00 AM EST
Can-Fite BioPharma Announces New Pre-Clinical Data Supporting a Novel Anti-NASH Mechanism of Action for Namodenoson
Jan 31, 2018 7:00 AM EST
Can-Fite to Present at BIO CEO & Investor Conference
<< Previous
1
2
3
4
Next >>
Show All
